News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

China National Biotech Group Institute Buys Vaccine Conjugate Technology From FinaBio


8/21/2012 10:05:12 AM

by Richard Daverman, PhD

August 20, 2012 -- The Chengdu Institute of Biological Products (CDIBP) has licensed technology for producing less-expensive conjugate vaccines from Fina Biosolutions LLC, a Maryland company that provides protein purification and bioconjugation services. CDIBP will use the technology to develop pneumococcal conjugate vaccines for the China market. CDIBP is a subsidiary of China National Biotec Group (CNBG), which is part of China National Pharmaceutical Group Corporation (Sinopharm). CDIPB will pay FinaBio an upfront fee, milestone payments and royalties. More details....


Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES